Association between duration of smoking abstinence before non-small-cell lung cancer diagnosis and survival: a retrospective, pooled analysis of cohort studies.
Journal
The Lancet. Public health
ISSN: 2468-2667
Titre abrégé: Lancet Public Health
Pays: England
ID NLM: 101699003
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
received:
23
02
2023
revised:
19
06
2023
accepted:
20
06
2023
medline:
28
8
2023
pubmed:
27
8
2023
entrez:
26
8
2023
Statut:
ppublish
Résumé
The association between duration of smoking abstinence before non-small-cell lung cancer (NSCLC) diagnosis and subsequent survival can influence public health messaging delivered in lung-cancer screening. We aimed to assess whether the duration of smoking abstinence before diagnosis of NSCLC is associated with improved survival. In this retrospective, pooled analysis of cohort studies, we used 26 cohorts participating in Clinical Outcomes Studies of the International Lung Cancer Consortium (COS-ILCCO) at 23 hospitals. 16 (62%) were from North America, six (23%) were from Europe, three (12%) were from Asia, and one (4%) was from South America. Patients enrolled were diagnosed between June 1, 1983, and Dec 31, 2019. Eligible patients had smoking data before NSCLC diagnosis, epidemiological data at diagnosis (obtained largely from patient questionnaires), and clinical information (retrieved from medical records). Kaplan-Meier curves and multivariable Cox models (ie, adjusted hazard ratios [aHRs]) were generated with individual, harmonised patient data from the consortium database. We estimated overall survival for all causes, measured in years from diagnosis date until the date of the last follow-up or death due to any cause and NSCLC-specific survival. Of 42 087 patients with NSCLC in the COS-ILCCO database, 21 893 (52·0%) of whom were male and 20 194 (48·0%) of whom were female, we excluded 4474 (10·6%) with missing data. Compared with current smokers (15 036 [40·0%] of 37 613), patients with 1-3 years of smoking abstinence before NSCLC diagnosis (2890 [7·7%]) had an overall survival aHR of 0·92 (95% CI 0·87-0·97), patients with 3-5 years of smoking abstinence (1114 [3·0%]) had an overall survival aHR of 0·90 (0·83-0·97), and patients with more than 5 years of smoking abstinence (10 841 [28·8%]) had an overall survival aHR of 0·90 (0·87-0·93). Improved NSCLC-specific survival was observed in 4301 (44%) of 9727 patients who had quit cigarette smoking and was significant at abstinence durations of more than 5 years (aHR 0·87, 95% CI 0·81-0·93). Results were consistent across age, sex, histology, and disease-stage distributions. In this large, pooled analysis of cohort studies across Asia, Europe, North America, and South America, overall survival was improved in patients with NSCLC whose duration of smoking abstinence before diagnosis was as short as 1 year. These findings suggest that quitting smoking can improve overall survival, even if NSCLC is diagnosed at a later lung-cancer screening visit. These findings also support the implementation of public health smoking cessation strategies at any time. The Alan B Brown Chair, The Posluns Family Fund, The Lusi Wong Fund, and the Princess Margaret Cancer Foundation.
Sections du résumé
BACKGROUND
The association between duration of smoking abstinence before non-small-cell lung cancer (NSCLC) diagnosis and subsequent survival can influence public health messaging delivered in lung-cancer screening. We aimed to assess whether the duration of smoking abstinence before diagnosis of NSCLC is associated with improved survival.
METHODS
In this retrospective, pooled analysis of cohort studies, we used 26 cohorts participating in Clinical Outcomes Studies of the International Lung Cancer Consortium (COS-ILCCO) at 23 hospitals. 16 (62%) were from North America, six (23%) were from Europe, three (12%) were from Asia, and one (4%) was from South America. Patients enrolled were diagnosed between June 1, 1983, and Dec 31, 2019. Eligible patients had smoking data before NSCLC diagnosis, epidemiological data at diagnosis (obtained largely from patient questionnaires), and clinical information (retrieved from medical records). Kaplan-Meier curves and multivariable Cox models (ie, adjusted hazard ratios [aHRs]) were generated with individual, harmonised patient data from the consortium database. We estimated overall survival for all causes, measured in years from diagnosis date until the date of the last follow-up or death due to any cause and NSCLC-specific survival.
FINDINGS
Of 42 087 patients with NSCLC in the COS-ILCCO database, 21 893 (52·0%) of whom were male and 20 194 (48·0%) of whom were female, we excluded 4474 (10·6%) with missing data. Compared with current smokers (15 036 [40·0%] of 37 613), patients with 1-3 years of smoking abstinence before NSCLC diagnosis (2890 [7·7%]) had an overall survival aHR of 0·92 (95% CI 0·87-0·97), patients with 3-5 years of smoking abstinence (1114 [3·0%]) had an overall survival aHR of 0·90 (0·83-0·97), and patients with more than 5 years of smoking abstinence (10 841 [28·8%]) had an overall survival aHR of 0·90 (0·87-0·93). Improved NSCLC-specific survival was observed in 4301 (44%) of 9727 patients who had quit cigarette smoking and was significant at abstinence durations of more than 5 years (aHR 0·87, 95% CI 0·81-0·93). Results were consistent across age, sex, histology, and disease-stage distributions.
INTERPRETATION
In this large, pooled analysis of cohort studies across Asia, Europe, North America, and South America, overall survival was improved in patients with NSCLC whose duration of smoking abstinence before diagnosis was as short as 1 year. These findings suggest that quitting smoking can improve overall survival, even if NSCLC is diagnosed at a later lung-cancer screening visit. These findings also support the implementation of public health smoking cessation strategies at any time.
FUNDING
The Alan B Brown Chair, The Posluns Family Fund, The Lusi Wong Fund, and the Princess Margaret Cancer Foundation.
Identifiants
pubmed: 37633678
pii: S2468-2667(23)00131-7
doi: 10.1016/S2468-2667(23)00131-7
pmc: PMC10540150
mid: NIHMS1929205
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e691-e700Subventions
Organisme : NHLBI NIH HHS
ID : HHSN268201600018C
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA076292
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201600003C
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201600004C
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201600001C
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA209414
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA167462
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA063673
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201600002C
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA167462
Pays : United States
Organisme : NCI NIH HHS
ID : U19 CA203654
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests We declare no competing interests.
Références
J Oncol Pract. 2018 May;14(5):e269-e279
pubmed: 29676948
J Thorac Oncol. 2022 May;17(5):623-636
pubmed: 34995798
Oncologist. 2011;16(12):1784-92
pubmed: 22135122
Lung Cancer. 2005 Feb;47(2):165-72
pubmed: 15639715
Lancet Oncol. 2002 Aug;3(8):461-9
pubmed: 12147432
Lancet Oncol. 2017 Dec;18(12):e754-e766
pubmed: 29208441
JAMA Netw Open. 2020 Nov 2;3(11):e2025102
pubmed: 33196807
Cancer. 2022 May 15;128(10):1976-1986
pubmed: 35143041
Cancer. 2013 Feb 15;119(4):847-53
pubmed: 23023590
Otolaryngol Head Neck Surg. 2010 Sep;143(3):331-6
pubmed: 20723767
N Engl J Med. 2011 Aug 4;365(5):395-409
pubmed: 21714641
N Engl J Med. 1993 Jan 21;328(3):159-63
pubmed: 8417381
Int J Nanomedicine. 2018 Oct 04;13:6049-6058
pubmed: 30323592
Ann Thorac Surg. 2009 Aug;88(2):362-70; discussion 370-1
pubmed: 19632374
Eur Respir J. 2016 Sep;48(3):889-902
pubmed: 27174888
J Thorac Oncol. 2014 Jul;9(7):917-926
pubmed: 24926542
Transl Lung Cancer Res. 2019 May;8(Suppl 1):S88-S94
pubmed: 31211109
Am J Epidemiol. 2012 Oct 1;176(7):573-85
pubmed: 22986146
Lung Cancer. 2006 Sep;53(3):375-80
pubmed: 16814423
Int J Cancer. 2017 Apr 15;140(8):1789-1795
pubmed: 28073149
N Engl J Med. 2020 Feb 6;382(6):503-513
pubmed: 31995683
J Natl Cancer Inst. 2018 Nov 1;110(11):1201-1207
pubmed: 29788259
Nicotine Tob Res. 2019 Mar 30;21(4):497-504
pubmed: 29351659
CA Cancer J Clin. 2022 Sep;72(5):405-406
pubmed: 36069379
Sci Rep. 2020 Mar 9;10(1):4375
pubmed: 32152345
CA Cancer J Clin. 2004 Mar-Apr;54(2):78-93
pubmed: 15061598
J Arthroplasty. 2021 Oct;36(10):3367-3371
pubmed: 34565525
N Engl J Med. 2008 Sep 25;359(13):1367-80
pubmed: 18815398
J Natl Cancer Inst. 2015 Mar 03;107(4):
pubmed: 25739419
Tanaffos. 2012;11(1):12-7
pubmed: 25191395
J Natl Cancer Inst. 2021 Aug 2;113(8):1065-1073
pubmed: 33484569
J Thorac Oncol. 2022 May;17(5):596-598
pubmed: 35465964
Nicotine Tob Res. 2016 Jan;18(1):17-24
pubmed: 25746779
J Thorac Oncol. 2015 Jul;10(7):1014-9
pubmed: 26102442
J Thorac Oncol. 2019 Sep;14(9):1594-1607
pubmed: 31163278
CA Cancer J Clin. 2013 Mar-Apr;63(2):107-17
pubmed: 23315954
CA Cancer J Clin. 2021 Jul;71(4):283-284
pubmed: 34061366